Efficacy and Safety of Sofosbuvir-based Drugs for the Treatment of Patients with Chronic Hepatitis C Genotype 3： A Single Centre Real-world Retrospective Analysis

Yanwen XU; Xin WANG; Hua JIANG; Chenchen LIANG; Li LIU; Shenghao LI; Jianpeng GAO

doi:10.12259/j.issn.2095-610X.S20221115

Volume 43 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(11): 124-129

Yanwen XU, Xin WANG, Hua JIANG, Chenchen LIANG, Li LIU, Shenghao LI, Jianpeng GAO. Efficacy and Safety of Sofosbuvir-based Drugs for the Treatment of Patients with Chronic Hepatitis C Genotype 3： A Single Centre Real-world Retrospective Analysis[J]. Journal of Kunming Medical University, 2022, 43(11): 124-129. doi: 10.12259/j.issn.2095-610X.S20221115

Citation:

Yanwen XU, Xin WANG, Hua JIANG, Chenchen LIANG, Li LIU, Shenghao LI, Jianpeng GAO. Efficacy and Safety of Sofosbuvir-based Drugs for the Treatment of Patients with Chronic Hepatitis C Genotype 3： A Single Centre Real-world Retrospective Analysis[J]. Journal of Kunming Medical University, 2022, 43(11): 124-129. doi: 10.12259/j.issn.2095-610X.S20221115

Citation:

Yanwen XU, Xin WANG, Hua JIANG, Chenchen LIANG, Li LIU, Shenghao LI, Jianpeng GAO. Efficacy and Safety of Sofosbuvir-based Drugs for the Treatment of Patients with Chronic Hepatitis C Genotype 3： A Single Centre Real-world Retrospective Analysis[J]. Journal of Kunming Medical University, 2022, 43(11): 124-129. doi: 10.12259/j.issn.2095-610X.S20221115

PDF( 901 KB)

Efficacy and Safety of Sofosbuvir-based Drugs for the Treatment of Patients with Chronic Hepatitis C Genotype 3： A Single Centre Real-world Retrospective Analysis

doi: 10.12259/j.issn.2095-610X.S20221115

1.
School of Public Health，Dali University，Dali Yunnan 671013
2.
Dept. of Digestive Diseases，The Forth Affiliated Hospital of Harbin Medical University，Harbin Heilongjiang 150001
3.
Dept. of Digestive Diseases，Kuming Yan’an Hospital，Kunming Yunnan 650051
4.
Dept. of Hepatology，The Third People’s Hospital of Kunming，Kunming Yunnan 650041，China

Received Date: 2022-06-27
Available Online: 2022-10-28
Publish Date: 2022-11-14

Abstract

Abstract

Objective To study the efficacy and safety of real-world sofosbuvir/velpatasvir （SOF/VEL） in combination with or without ribavirin （RBV） in the treatment of patients with chronic hepatitis C （CHC） genotype 3 in Yunnan. Methods A total of 219 patients with genotype 3 CHC between January 2018 and March 2022 were selected and treated with SOF/VEL in combination with or without RBV for 12 weeks or 24 weeks with a 12-week follow-up after discontinuation of the drug. General demographic data, HCV RNA quantification, liver function, and liver stiffness measurements were collected from patients. Results Among 219 patients with genotype 3 CHC, abnormal biochemical parameters and liver hardness values were significantly lower than baseline at 12 weeks of discontinuation, with a sustained viral response rate of 95.4% （209/219）. 60 cases reported mild adverse effects, mainly anemia, malaise and headache, and no serious adverse effects were observed. Conclusions SOF/VEL in combination with or without RBV regimen can result in high response rates in patients with hepatitis C genotype 3 without cirrhosis or combined with compensated cirrhosis, but lower response rates in patients with hepatitis C genotype 3 in combination with chronic liver failure. Patients may have mild adverse effects and an acceptable safety profile with this regimen.
- Chronic hepatitis C,
- Genotype 3,
- Children,
- Adolescents,
- Compensated liver cirrhosis,
- Chronic liver failure,
- Real-world,
- Sofosbuvir/Velpatasvir

FullText(HTML)

References(23)

References

[1]	李健,庞琳,王晓春,等. 中国丙型肝炎防治进展与展望[J]. 中国艾滋病性病,2022,28(7):761-765. doi: 10.13419/j.cnki.aids.2022.07.01
[2]	Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015:a modelling study[J]. Lancet Gastroenterol Hepatol,2017,2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9
[3]	McHutchison J G,Gordon S C,Schiff E R,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group[J]. N Engl J Med,1998,339(21):1485-1492. doi: 10.1056/NEJM199811193392101
[4]	Poynard T,Marcellin P,Lee S S,et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)[J]. Lancet,1998,352(9138):1426-1432. doi: 10.1016/S0140-6736(98)07124-4
[5]	Kanwal F,Kramer J R,Ilyas J,et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U. S. Veterans with HCV[J]. Hepatology,2014,60(1):98-105. doi: 10.1002/hep.27095
[6]	Tapper E B,Afdhal N H. Is 3 the new 1:perspectives on virology,natural history and treatment for hepatitis C genotype 3[J]. J Viral Hepat,2013,20(10):669-677. doi: 10.1111/jvh.12168
[7]	Chen Y,Yu C,Yin X,et al. Hepatitis C virus genotypes and subtypes circulating in Mainland China[J]. Emerg Microbes Infect,2017,6(11):e95.
[8]	中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 中国病毒病杂志,2020,10(1):26-46. doi: 10.16505/j.2095-0136.2020.0008
[9]	何勇,张振华,刘忠萍,等. 中国HCV基因型分布的Meta分析[J]. 实用肝脏病杂志,2021,24(5):693-696. doi: 10.3969/j.issn.1672-5069.2021.05.022
[10]	Wei L,Wang G,Alami N N,et al. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia:two multicentre,phase 3 studies- a randomised,double-blind study (VOYAGE-1) and an open-label,single-arm study (VOYAGE-2)[J]. Lancet Gastroenterol Hepatol,2020,5(9):839-849. doi: 10.1016/S2468-1253(20)30086-8
[11]	Mei Y Y,Chen Y M,Wu Y K,et al. Efficacy and safety of sofosbuvir-based direct-acting antiviral agents treatment for patients with genotype 3/6 hepatitis C virus infection[J]. Can J Gastroenterol Hepatol,2020,2020:8872120.
[12]	Huang R,Rao H,Xie Q,et al. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection[J]. J Med Virol,2019,91(7):1313-1318. doi: 10.1002/jmv.25454
[13]	徐小元,丁惠国,李文刚,等. 肝硬化诊治指南[J]. 实用肝脏病杂志,2019,22(6):770-786. doi: 10.3969/j.issn.1672-5069.2019.06.004
[14]	中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 中华肝脏病杂志,2019,27(1):18-26. doi: 10.3760/cma.j.issn.1007-3418.2019.01.006
[15]	Wei B,Ji F,Yeo Y H,et al. Systematic review and meta-analysis:real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia[J]. BMJ Open Gastroenterol,2018,5(1):e000209. doi: 10.1136/bmjgast-2018-000209
[16]	Petruzziello A,Marigliano S,Loquercio G,et al. Global epidemiology of hepatitis C virus infection:An up-date of the distribution and circulation of hepatitis C virus genotypes[J]. World J Gastroenterol,2016,22(34):7824-7840. doi: 10.3748/wjg.v22.i34.7824
[17]	Wirth S,Rosenthal P,Gonzalez-Peralta R P,et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection[J]. Hepatology,2017,66(4):1102-1110. doi: 10.1002/hep.29278
[18]	Jonas M M, Romero R, Etienne M, et al. The safety and efficacy of sofosbuvir/velpatasvir in pediatric patients aged 6- < 18 years with chronic hepatitis C virus infection [R]. Presented at AASLD: The Liver Meeting, 2019.
[19]	徐强,张伟,马玉秀,等. 12周索磷布韦/维帕他韦方案治疗西北地区慢性丙型肝炎患者:一项真实世界多中心临床研究[J]. 中华肝脏病杂志,2021,29(11):1046-1052. doi: 10.3760/cma.j.cn501113-20201010-00548
[20]	Wong Y J,Thurairajah P H,Kumar R,et al. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort[J]. J Gastroenterol Hepatol,2021,36(5):1300-1308. doi: 10.1111/jgh.15324
[21]	杨宏,排云珍,章银娣,等. 云南德宏地区丙型肝炎病毒基因分型特点分析[J]. 中国感染与化疗杂志,2021,21(5):566-569. doi: 10.16718/j.1009-7708.2021.05.011
[22]	王志勇,李应,徐升,等. 云南楚雄丙型肝炎基因型分布的特点[J]. 中国现代医生,2019,57(11):5-11+15+169.
[23]	陈友惠,王辉,高建鹏,等. 云南省HCV合并HIV或HBV感染者HCV基因型分布及病毒学特征[J]. 胃肠病学和肝病学杂志,2021,30(11):1293-1297. doi: 10.3969/j.issn.1006-5709.2021.11.019

Relative Articles(20)

Relative Articles

[1]	Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411
[2]	Yanli MA, Cheng FENG, Liqing GUO, Xia GUO, Fengqiong ZHOU, Zhi-hui LIU, Yunhong MA. Application Value of Focused Solution Mode Nursing Intervention in Treatment Compliance and Quality of Life of Patients with Hepatitis C. Journal of Kunming Medical University, 2023, 44(2): 177-180. doi: 10.12259/j.issn.2095-610X.S20230212
[3]	Deng'ai DUAN, Yonghui ZHANG, Wei WANG, Xinju LIAO, Zhixiong ZHANG. Effect of Childhood Abuse on Non-suicidal Self-injury in Adolescents with First-episode Depression. Journal of Kunming Medical University, 2023, 44(3): 120-124. doi: 10.12259/j.issn.2095-610X.S20230304
[4]	Linlin XUE, Binghan LI, Chunyun LIU, Weikun LI, Lixian CHANG, Huimin LI, Yanwei QI, Li LIU. Establishment and Evaluation of a Nomogram for Predicting Potential Death in Patients with Hepatitis C Cirrhosis and Sepsis in General Wards. Journal of Kunming Medical University, 2023, 44(6): 113-119. doi: 10.12259/j.issn.2095-610X.S20230630
[5]	Yunli YANG, Na LI, Changming QIU, Junjie PU, Wei NIE, Zhigui LI. Effect of Ultrasound-guided Transmuscular Quadratus Lumborum Block for Postoperative Analgesia in Pediatric Patient Undergoing Hip Surgery. Journal of Kunming Medical University, 2023, 44(4): 88-92. doi: 10.12259/j.issn.2095-610X.S20230426
[6]	Kang HUANG, Zhirong ZHAO, Haiwen LI, Ti WU, Ting JIA, Lu WANG, Nihong LU, Yongrui YANG. Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection. Journal of Kunming Medical University, 2023, 44(11): 126-134. doi: 10.12259/j.issn.2095-610X.S20231119
[7]	Li LIU, Jun-yi LI, Chun-yun LIU, Ying-rong DU, Jian-peng GAO, Hui-ming LI, Wei-kun LI, Yan-wei QI, Hui WANG. Effect of Tenofovir Combined with Ganshuang Granule on Hemodynamics of Portal Vein System in Hepatitis B Liver Cirrhosis. Journal of Kunming Medical University, 2021, 42(11): 134-139. doi: 10.12259/j.issn.2095-610X.S20211125
[8]	Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B. Journal of Kunming Medical University, 2021, 42(1): 89-93. doi: 10.12259/j.issn.2095-610X.S20210141
[9]	Zhao XIANG, Jin-hui YANG. Clinical Efficacy of Non-biological Artificial Liver in 112 Patients with Liver Failure. Journal of Kunming Medical University, 2021, 42(12): 140-144. doi: 10.12259/j.issn.2095-610X.S20211034
[10]	Sheng-hao LI, Jie DING, Qing-qing WANG, Si-qi LIU, Li-juan HUA, Jin-yu DUAN, Bao-li BO, An-rui DU, Guo-ji CHANG, Jun-yi LI. Influencing Factors of Moderate to Severe Liver Injury in Patients with Chronic Hepatitis B and NAFLD. Journal of Kunming Medical University, 2021, 42(7): 77-82. doi: 10.12259/j.issn.2095-610X.S20210712
[11]	Yong-rui YANG, Hai-wen LI, Zhi-rong ZHAO, Lu WANG, Ting JIA, Zhi-jian DONG, Xiao-fei LI, Ni-hong LU. Clinical Efficacy and Safety of Sofosbuvir and Vipatavir in the Treatment of Patients with Chronic Hepatitis C and HCV/HIV co-infection. Journal of Kunming Medical University, 2021, 42(7): 130-136. doi: 10.12259/j.issn.2095-610X.S20210722
[12]	Zhi-rong ZHAO, Hai-wen LI, Xiao-fei LI, Ni-hong LU, Yong-rui YANG. Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C. Journal of Kunming Medical University, 2021, 42(3): 98-103. doi: 10.12259/j.issn.2095-610X.S20210325
[13]	Pu Dong , Li Xiao Fei , Yu Ting Ting , Wang Hong Ying , Zhang Run Wu , Li Li Hua , Bai Jing , Ding Cai Mei , Li Dong Ling , Yang Yong Rui . . Journal of Kunming Medical University, 2020, 41(06): 149-155.
[14]	Li-xian YUAN, Hong-tao ZHANG, Rui LI, Kun-rui CHEN, Kun-qian CHEN, An-shu XU. Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma. Journal of Kunming Medical University, 2020, 41(12): 80-84. doi: 10.12259/j.issn.2095-610X.S20201223
[15]	He Hai Yu . The Expression of GP73 in Serum and Tissues of Patients with Chronic Hepatitis B，Liver Cirrhosis and Primary Live r Cancer. Journal of Kunming Medical University,
[16]	Zhou Ying . The Influence of GSH Combined ETV on Liver Fibrosis Indexes of Patients with CHB. Journal of Kunming Medical University,
[17]	Xu Hui Ling . . Journal of Kunming Medical University,
[18]	Yang Yong Rui . . Journal of Kunming Medical University,
[19]	Yang Yong Rui . . Journal of Kunming Medical University,
[20]	Su Ying . . Journal of Kunming Medical University,